Fierce Pharma Biopharma News & Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Appeals court again strikes down J&J's Texas two-step ploy
Jul 26, 2024 · Johnson & Johnson’s latest attempt to get a handle on its talc litigation using the controversial Texas two-step bankruptcy strategy has once again fallen flat after a federal …
Top 20 pharma companies by 2023 revenue - Fierce Pharma
Apr 15, 2024 · There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five …
Biogen - Fierce Pharma
After its first breakthrough Alzheimer’s disease treatment Aduhelm sputtered out, Biogen is harnessing its second shot at the market of nearly 7 million U.S. patients with its Eisai …
FDA panel says more testing needed to solve Moderna trial halt
Dec 13, 2024 · The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV vaccines.
Pfizer’s latest Viagra TV ad pitches mobile texting for discounts
Jan 19, 2017 · In the case of Viagra, texting the savings code results in a message that requires consumers to first reply “Yes” to opt into the program and agree to “terms and complete …
AbbVie CEO telegraphs retirement and prepares to pass baton to …
Feb 20, 2024 · During the final quarter of 2023, sales of Humira plummeted nearly 41% to $3.3 billion globally. The rate of erosion apparently gained steam in the fourth quarter and outpaced …
After trial win, Axsome eyes FDA filing for narcolepsy hopeful
Nov 27, 2024 · Once a controversial European depression treatment that never made it to the U.S. market, reboxetine may soon see new life under Axsome Therapeutics' stewardship.. …
The top 15 blockbuster patent expirations coming this decade
Looking out over the next decade, some of the biggest drugs in the industry will tumble off the patent cliff, putting pharma giants in the hot seat as investors clamor for their next blockbuster.
For 2nd time in three months, Syndax wins FDA nod for a new drug
Nov 18, 2024 · The consecutive nods come from a 19-year-old Massachusetts-based company that started the year with a headcount of 184, up from 107 at the beginning of 2023.